Pfizer received approval from the FDA for Geodon (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder. The efficacy and safety of Geodon for the adjunctive maintenance treatment were studied in a six-month, double-blind, randomized...